

| | | | | | |
|--|---|--------------------------|-------------------|------------------------|------------------------------------|
| Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/454,481 | | |
| | | Filing Date | December 3, 1999 | | |
| | | First Named Inventor | ALLISON, James P. | | |
| | | Art Unit | 1642 | | |
| | | Examiner Name | Rawlings, S.L. | | |
| Sheet | 1 | of | 5 | Attorney Docket Number | A-68668/RFT/TAL/CYO (465174-00312) |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|-----------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| SR | A1 | 5,434,131 | 07-18-1995 | Linsley et al. | |
| | A2 | 5,770,197 | 06-23-1998 | Linsley et al. | |
| | A3 | 5,773,253 | 06-30-1998 | Linsley et al. | |
| | A4 | 5,844,095 | 12-01-1998 | Linsley et al. | |
| | A5 | 5,851,795 | 12-22-1998 | Linsley et al. | |
| | A6 | 5,869,057 | 02-09-1999 | Rock | |
| | A7 | 5,885,796 | 03-23-1999 | Linsley et al. | |
| | A8 | 5,968,510 | 10-19-1999 | Linsley et al. | |
| | A9 | 5,977,318 | 11-02-1999 | Linsley et al. | |
| | A10 | 6,090,914 | 07-18-2000 | Linsley et al. | |
| | A11 | 6,323,027 B1 | 11-27-2001 | Burkly et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|-----------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁵ |
| SR | B1 | WO 95/01994 A1 | 01-19-1995 | Synergen, Inc. | | |
| | B2 | WO 95/34320 A2 | 12-22-1995 | Regents of the University of Minnesota | | |
| | B3 | WO 96/14865 A1 | 05-23-1996 | Repligen Corp. | | |
| | B4 | WO 00/32231 A1 | 06-08-2000 | The Regents of the University of California | | |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ⁵ |
| SR | C1 | ALLISON, J.P., et al., "The yin and yang of T cell co-stimulation," <i>Science</i> 270(5238):932-933 (Nov. 1995). | | | |
| ↓ | C2 | BELLDEGRUN, A., et al., "Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity," <i>Cancer Res.</i> Jan. 1988, 481:206-214. | | | |
| | C3 | BLUESTONE, J.A., "New perspectives of CD28-B7-mediated T cell costimulation," <i>Immunity</i> 2(6):555-559 (Jun. 1995). | | | |
| | C4 | BRUNET, J.-F., et al., "A new member of the immunoglobulin superfamily - CTLA-4," <i>Nature</i> 328(6127):267-270 (Jul. 1987). | | | |
| Y | C5 | CHAUDHARY, J., et al., "Caloxin: a novel plasma membrane Ca ²⁺ pump inhibitor," <i>Am. J. Physiol. Cell Physiol.</i> 280(4):C1027-C1030 (Apr. 2001). | | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 6/25/04 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------------------|
| Application Number | 09/454,481 |
| Filing Date | December 3, 1999 |
| First Named Inventor | ALLISON, James P. |
| Art Unit | 1642 |
| Examiner Name | Rawlings, S.L. |
| Attorney Docket Number | A-68668/RFT/TAL/CYO (465174-00312) |

Sheet

2

of

5

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| SR | C6 | CHEN, L., et al., "Costimulation of antitumor activity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4," <i>Cell</i> 71(7):1093-1102 (Dec. 1992). | |
| | C7 | DAMLE, N., et al., "Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7," <i>J. Immunol.</i> 152(6):2686-2697 (Mar. 1994). | |
| | C8 | DARIAVACH, P., et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>Eur. J. Immunol.</i> 18(12):1901-1905 (Dec. 1988). | |
| | C9 | De WAAL MALEFYT, R., et al., "CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 23(2):418-424 (Feb. 1993). | |
| | C10 | DeVITA, V., "The relationship between tumor mass and resistance to chemotherapy," <i>Cancer</i> 51(7):1209-1220 (Apr. 1983). | |
| | C11 | DEVILIN, J., et al., "Random peptide libraries: a source of specific protein binding molecules," <i>Science</i> 249(4967):404-406 (Jul. 1990). | |
| | C12 | FREEMAN, G.J., et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," <i>Science</i> 262(5135):907-909 (Nov. 1993). | |
| | C13 | GOODSON, R., et al., "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display," <i>Proc. Natl. Acad. Sci. USA</i> 91(15):7129-7133 (Jul. 1994). | |
| | C14 | GRIBBEN, J., et al., "CTLA4 mediates antigen-specific apoptosis of human T cells," <i>Proc. Natl. Acad. Sci. USA</i> 92(3):811-815 (Jan. 1995). | |
| | C15 | GROSS, J., et al., "Identification and distribution of the costimulatory receptor CD28 in the mouse," <i>J. Immunol.</i> 149(2):380-388 (Jul. 1992). | |
| | C16 | GROSS, J., et al., "The murine homologue of the T lymphocyte antigen CD28," <i>J. Immunol.</i> 144(8):3201-3210 (Apr. 1990). | |
| | C17 | HARDING, F., et al., "CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help," <i>J. Exp. Med.</i> 177(6):1791-1796 (Jun. 1993). | |
| | C18 | HARDING, F., et al., "CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> 356(6370):607-609 (Apr. 1992). | |
| | C19 | HARPER, K., et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," <i>J. Immunol.</i> 147(5):1037-1044 (Aug. 1991). | |
| | C20 | HODI, J.S., et al., "Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients," <i>Proc. Natl. Acad. Sci. USA</i> 100(8):4712-4717 (Apr. 2003). | |
| | C21 | HUANG, Y.W., et al., "Immunotherapy of multiple myeloma," <i>Stem Cells</i> 13(2):123-134 (Mar. 1995). | |
| | C22 | JENKINS, M., et al., "T-cell unresponsiveness <i>in vivo</i> and <i>in vitro</i> : fine specificity induction and molecular characterization of the unresponsive state," <i>Immunol. Rev.</i> 95():113-135 (Feb. 1987). | |

Examiner
Signature

Date
Considered

6/25/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



| | | | | | |
|---|---|--------------------------|-------------------|------------------------|------------------------------------|
| Substitute for form 1449A/PTO (Modified) | | Complete if Known | | | |
| | | Application Number | 09/454,481 | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Filing Date | December 3, 1999 | | |
| | | First Named Inventor | ALLISON, James P. | | |
| | | Art Unit | 1642 | | |
| | | Examiner Name | Rawlings, S.L. | | |
| Sheet | 3 | of | 5 | Attorney Docket Number | A-68668/RFT/TAL/CYO (465174-00312) |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | P ⁶ |
| se | C23 | JENKINS, M.K., "The ups and downs of T cell activation," <i>Immunity</i> 1(6):444-446 (Sep. 1994). | |
| | C24 | JUNE, C.H., et al., "The B7 and CD28 receptor families," <i>Immunol. Today</i> 15(7):321-331 (Jul. 1994). | |
| | C25 | JUNE, C.H., et al., "Role of the CD28 receptor in T-cell activation," <i>Immunol. Today</i> 11(6):211-216 (Jun. 1990). | |
| | C26 | KRUMMEL, M., et al., "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," <i>J. Exp. Med.</i> 182(2):459-465 (Aug. 1995). | |
| | C27 | KWON, E., et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc. Natl. Acad. Sci. USA</i> 94(15):8099-8103 (Jul. 1997). | |
| | C28 | LANE, P., et al., "Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human $\gamma 1$," <i>Immunology</i> 80(1):56-61 (Sep. 1993). | |
| | C29 | LENSCHOW, D.J., et al., "Expression and functional significance of an additional ligand for CTLA-4," <i>Proc. Natl. Acad. Sci. USA</i> 90(23):11054-11058 (Dec. 1993). | |
| | C30 | LENSCHOW, D.J., et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," <i>Science</i> 257(5071):789-792 (Aug. 1992). | |
| | C31 | LIN, H., et al., "Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4lg plus donor-specific transfusion," <i>J. Exp. Med.</i> 178(5):1801-1806 (Nov. 1993). | |
| | C32 | LINDSTEN, T., et al., "Characterization of CTLA-4 structure and expression on human cells," <i>J. Immunol.</i> 151(7):3489-3499 (Oct. 1993). | |
| | C33 | LINSLEY, P., et al., "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes," <i>J. Exp. Med.</i> 176(6):1595-1604 (Dec. 1992). | |
| | C34 | LINSLEY, P., et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," <i>J. Exp. Med.</i> 174(3):561-569 (Sep. 1991). | |
| | C35 | LINSLEY, P., et al., "Distinct roles for CD28 and cytotoxic lymphocyte-associated molecule-4 receptors during T cell activation," <i>J. Exp. Med.</i> 182(2):282-285 (Aug. 1995). | |
| | C36 | LINSLEY, P., et al., "Immunosuppressive in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> 257(5071):792-795 (Aug. 1992). | |
| | C37 | LINSLEY, P., et al., "Lymphocyte activation: T-cell regulation by CTLA-4," <i>Curr. Biol.</i> 6(4):398-400 (Apr. 1996). | |
| | C38 | LINSLEY, P., et al., "The role of the CD28 receptor during T cell responses to antigen," <i>Annu. Rev. Immunol.</i> 11():191-212 (1993). | |
| | C39 | NELSON, A.J., et al., "Medullary thymic epithelium expresses a ligand for CTLA4 in situ and in vitro," <i>J. Immunol.</i> 151(5):2453-2461 (Sep. 1993). | |
| | C40 * | OLDENBURG, K., et al., "Peptide ligands for a sugar-binding protein isolated from a random peptide library," <i>Proc. Natl. Acad. Sci. USA</i> 89(12):5393-5397 (Jun. 1992). | |
| | C41 | PEACH, R., et al., "Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1," <i>J. Exp. Med.</i> 180(6):2049-2058 (Dec. 1994). | |


| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 6/25/04 |
|-----------------------|--|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



| | | | | | |
|---|---|--------------------------|-------------------|------------------------|------------------------------------|
| Substitute for form 1449A/PTO (Modified) | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/454,481 | | |
| | | Filing Date | December 3, 1999 | | |
| | | First Named Inventor | ALLISON, James P. | | |
| | | Art Unit | 1642 | | |
| | | Examiner Name | Rawlings, S.L. | | |
| Sheet | 4 | of | 5 | Attorney Docket Number | A-68668/RFT/TAL/CYO (465174-00312) |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|---|
| SE | C42 * | PHAN, G.Q., et al., "Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma," <i>Proc. Natl. Acad. Sci. USA</i> 100(14):8372-8377 (Jul. 2003). | |
| | C43 | ROSENBERG, S., et al., "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone," <i>New Engl. J. Med.</i> 316(15):891-897 (Apr. 1987). | |
| | C44 | ROSENTHAL, F., et al., "Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity," <i>Curr. Opin. Oncol.</i> 6(6):611-615 (Nov. 1994). | |
| | C45 | SCHWARTZ, R., "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> 71(7):1065-1068 (Dec. 1992). | |
| | C46 * | SPARKS, A., et al., "Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries," <i>J. Biol. Chem.</i> 269(39):23853-23856 (Sep. 1994). | |
| | C47 | TJOA, B., et al., "Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection," <i>Cancer Res.</i> 54(1):204-208 (Jan. 1994). | |
| | C48 | TOWNSEND, S., et al., "Specificity and longevity of antitumor immune responses induced by B7-transfected tumors," <i>Cancer Res.</i> 54(24):6477-6483 (Dec. 1994). | |
| | C49 | TRAVIS, J., "A stimulating new approach to cancer treatment," <i>Science</i> 259(5093):310-311 (Jan. 1993). | |
| | C50 | TURKA, L., et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 89(22):11102-11105 (Nov. 1992). | |
| | C51 | VAN ELSAS, A., et al., "Blockade of CTLA-4 cinvubed wutg a GM-CSF vaccine cures mice from the highly tumorigenic, poorly immunogenic melanoma B16-BL6, and induces depigmentation," <i>FASEB J.</i> 12(5):A908 (Mar. 1998) (Abstract #5258). | |
| | C52 | VAN ELSAS, A., et al., "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation," <i>J. Exp. Med.</i> 190(3):355-366 (Aug. 1999). | |
| | C53 | VAN SEVENTER, G., et al., "Roles of multiple accessory molecules in T-cell activation," <i>Curr. Opin. Immunol.</i> 3(3):294-303 (Jun. 1991). | |
| | C54 | WATERHOUSE, P., et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," <i>Science</i> 270(5238):985-988 (Nov. 1995). | |
| | C55 | WELLS, A., et al., "Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy," <i>J. Clin. Invest.</i> 108(6):895-903 (Sep. 2001). | |
| | C56 | WOODLE, E.S., et al., " <i>In vivo</i> administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells," <i>Transplantation</i> 61(5):798-803 (Mar. 1996). | |
| | C57 | WU, Y., et al., "CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion," <i>J. Exp. Med.</i> 185(7):1327-1335 (Apr. 1997). | |
| | Y | C58 * | XU, H., et al., "A novel PCNA-binding motif identified by the panning of a random peptide display library," <i>Biochemistry</i> 40(14):4512-4520 (Apr. 2001). |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 6/28/04 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial-number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



| | | | | | |
|--|---|----|---|--------------------------|------------------------------------|
| Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/454,481 |
| | | | | Filing Date | December 3, 1999 |
| | | | | First Named Inventor | ALLISON, James P. |
| | | | | Art Unit | 1642 |
| | | | | Examiner Name | Rawlings, S.L. |
| Sheet | 5 | of | 5 | Attorney Docket Number | A-68668/RFT/TAL/CYO (465174-00312) |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|--------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | ² |
| SR | C59 * | YANOFISKY, S., et al., "High affinity type I interleukin 1 receptor antagonists discovered by screenin grecombinant peptide libraries," <i>Proc. Natl. Acad. Sci. USA</i> 93(14):7381-7386 (Jul. 1996). | — |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 6/25/04 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2